InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
BioPharma Dive5d
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
Pfizer appoints former J&J executive to lead obesity drug development
Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...
BioSpace4d
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
Fierce Pharma3d
Want a piece of Lilly's $27B US manufacturing investment? Please send your application
Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitche | Eli ...
Indianapolis Business Journal1d
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...
BioSpace4d
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
Pfizer boosts anti-obesity efforts: adds former J&J exec. as chief internal medicine officer
Pfizer (NYSE:PFE) has named James List, a former Johnson & Johnson (NYSE:JNJ) executive, as the company’s new chief internal ...